Ligand Pharmaceuticals Net Worth
Ligand Pharmaceuticals Net Worth Breakdown | LGND |
Ligand Pharmaceuticals Net Worth Analysis
Ligand Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ligand Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ligand Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ligand Pharmaceuticals' net worth analysis. One common approach is to calculate Ligand Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ligand Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ligand Pharmaceuticals' net worth. This approach calculates the present value of Ligand Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ligand Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ligand Pharmaceuticals' net worth. This involves comparing Ligand Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ligand Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Ligand Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ligand Pharmaceuticals' net worth research are outlined below:
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Rubric Capital Management LP Takes Position in Zevra Therapeutics, Inc. |
Ligand Pharmaceuticals Quarterly Good Will |
|
Ligand Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ligand Pharmaceuticals Incorporated. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ligand Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ligand Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ligand Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ligand Pharmaceuticals Incorporated backward and forwards among themselves. Ligand Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ligand Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-09-30 | 372.8 K | Rice Hall James & Associates, Llc | 2024-09-30 | 312.9 K | Ashford Capital Management Inc | 2024-09-30 | 310.4 K | Impax Asset Management Group Plc | 2024-09-30 | 280.2 K | Deutsche Bank Ag | 2024-06-30 | 270.2 K | Northern Trust Corp | 2024-09-30 | 262.8 K | Abrdn Plc | 2024-09-30 | 249.3 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 237 K | William Blair Investment Management, Llc | 2024-09-30 | 205.7 K | Blackrock Inc | 2024-06-30 | 2.9 M | Vanguard Group Inc | 2024-09-30 | 2 M |
Follow Ligand Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.32 B.Market Cap |
|
Project Ligand Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.07 | 0.07 |
When accessing Ligand Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ligand Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ligand Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Ligand Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ligand Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ligand Pharmaceuticals' management manipulating its earnings.
Evaluate Ligand Pharmaceuticals' management efficiency
Ligand Pharmaceuticals has return on total asset (ROA) of 0.013 % which means that it generated a profit of $0.013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.06 %, meaning that it created $0.06 on every $100 dollars invested by stockholders. Ligand Pharmaceuticals' management efficiency ratios could be used to measure how well Ligand Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ligand Pharmaceuticals' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.07, whereas Return On Equity is forecasted to decline to 0.07. At present, Ligand Pharmaceuticals' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 385.2 M, whereas Other Current Assets are forecasted to decline to about 3.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 40.52 | 42.55 | |
| Tangible Book Value Per Share | 13.33 | 14.00 | |
| Enterprise Value Over EBITDA | 11.98 | 9.53 | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | 11.98 | 9.53 | |
| Price Fair Value | 1.76 | 1.67 | |
| Enterprise Value | 2.6 B | 2.7 B |
Leadership effectiveness at Ligand Pharmaceuticals Incorporated is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 13.6656 | Revenue 152.4 M | Quarterly Revenue Growth 0.576 | Revenue Per Share 8.509 | Return On Equity 0.06 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ligand Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ligand Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ligand Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ligand Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Ligand Pharmaceuticals Earnings per Share Projection vs Actual
Ligand Pharmaceuticals Corporate Management
| Vincent Antle | Senior Capitsol | Profile | |
| Paul Hadden | Senior Development | Profile | |
| Michael Jeong | Head Relations | Profile | |
| Audrey WarfieldGraham | Chief Officer | Profile | |
| Karen MD | Senior Strategy | Profile | |
| Richard Baxter | Senior Operation | Profile | |
| Todd Pettingill | Sr. Manager - Corporate Development and Investor Relations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.